600873 梅花生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入18,215,447-2.49%25,069,28827,760,61227,937,15323,060,956
减:营业总成本15,834,728-4.89%21,862,60024,158,62322,990,08120,420,447
    其中:营业成本14,342,186-5.33%20,036,69922,297,12220,915,78418,585,713
               财务费用(13,954)-80.54%(117,264)(33,427)83,877176,935
               资产减值损失(9,348)403.30%(6,982)(5,415)(5,958)(20,500)
公允价值变动收益25,374189.56%14,826(38,116)32,687(22,024)
投资收益42,049102.72%30,1937,62724,365307,906
    其中:对联营企业和合营企业的投资收益(2,035)-51.04%(3,018)1,8463,074(354)
营业利润2,658,93016.94%3,491,2853,813,3935,160,1792,929,432
利润总额3,442,50546.99%3,349,4613,723,1365,152,7952,883,412
减:所得税费用417,41220.42%609,033542,186746,553456,108
净利润3,025,09251.61%2,740,4273,180,9504,406,2422,427,304
减:非控股权益----------25,056
股东净利润3,025,09251.61%2,740,4273,180,9504,406,2422,402,248

市场价值指针
每股收益 (元) *1.06055.88%0.9401.0601.4400.780
每股派息 (元) *----0.6020.4200.4000.400
每股净资产 (元) *5.74711.39%5.1094.8124.4423.428
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容